U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Merck breaks ground on new $1 billion biologics center of excellence in Wilmington, Delaware: Rahway, New Jersey Wednesday, April 30, 2025, 09:00 Hrs [IST] Merck, known as MSD out ...

Merck’s facility reportedly will be operational within three ... “The decision to build a new biologics facility in ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.